Lotus Health AI raises $41M to deliver free AI-powered primary care direct to consumers

Summary

Lotus Health AI raised $41 million across seed and Series A rounds led by Kleiner Perkins and CRV to build a direct-to-consumer AI primary care platform. Co-founder KJ Dhaliwal frames the opportunity around a simple fact: 100 million Americans lack access to primary care physicians, and Lotus estimates that 80% of primary care needs can be delivered virtually through prescriptions, lab orders, and referrals.

The product pairs AI-powered patient intake with licensed clinicians. Patients upload health data and chat with the AI, which performs image analysis for conditions like skin problems. The platform pulls in longitudinal records from prior EHRs, wearables, and insurance claims to give clinicians fuller context before they review and sign off on care decisions. Dhaliwal says this data aggregation layer enables what he calls agentic workflows and more accurate care at scale.

Dhaliwal's background is in consumer tech—he built a major South Asian dating app—and Lotus applies that playbook directly to healthcare. Rather than sell to hospitals or insurance companies, the company targets patients. Dhaliwal believes 80 to 90% of care is deliverable virtually, which would reduce bottlenecks at urgent care centers and ERs that today overflow with patients who do not need in-person treatment.

The revenue model starts with a free tier that includes optional ads and premium subscriptions that remove ads. The bigger opportunity, Dhaliwal says, is employer partnerships. Large self-insured companies are already asking to pay $50 per employee per month to give workers free primary care access, eliminating the time cost of driving to see a doctor or physician's assistant. He frames the long-term goal as reaching 10 million patients, noting that both fee-for-service and value-based care models fail when there are not enough doctors to deliver care at all.

On competition from major LLM providers adding health features, Dhaliwal sees it as net positive for adoption and normalization of AI in healthcare. The key moat is that large language models cannot treat patients. Lotus can write prescriptions, order labs, and issue diagnoses because it employs licensed clinicians. One of Lotus's investors is an OpenAI executive, and Dhaliwal frames that relationship as collaborative rather than competitive, pointing to the $5 trillion U.S. healthcare market and the waste that can be cut out of it.